Nomura Research in a July 19 research report says: “We reiterate buy on Biosensors (BIG), highlighting three key growth pillars: BioMatrix’s growing market acceptance, the valuable joint venture in China and growing royalty income from Terumo.
Posts Tagged ‘Biosensors’
Biosensors Int’l Group – Corporate moves
July 12th, 2010 |
No Comments
Dr Lincoln Chee Wang Jin has been appointed non-executive independent director wef July 28
Work experience: Independent non-executive director, Arana Therapeutics Ltd; CEO, Quality HealthCare Medical Services, Hong Kong
Biosensors +1.3%; Japan market is key catalyst, says Nomura
June 8th, 2010 |
No Comments
Biosensors (B20.SG) is up 1.3% at $0.765, rebounding from yesterday’s 4-week low of $0.755, according to Dow Jones.
Biosensors Int’l Group – Corporate moves
June 1st, 2010 |
No Comments
Jeffrey Bryan Jump has been appointed director, president & CEO wef July 1
Work experience: MD, Europe, Middle East and Africa, Biosensors Int’l; CEO, Xitact Medical Simulation
Biosensors off 0.6%; risk of China delay, says Credit Suisse
May 31st, 2010 |
No Comments
Biosensors (B20.SG) is down 1.3% at $0.785, extending Thursday’s 1.2% fall, as investors continue to unload shares following release of heart-stent maker’s fiscal FY10 results late last week, according to Dow Jones.
May 27: CapitaCommercial Trust, Boustead, Biosensors, Transcu, healthcare providers
May 27th, 2010 |
No Comments
Singapore’s benchmark Straits Times Index rose 1.7% to 2,696.02 points on Wednesday.
Singapore stocks are expected to face selling pressure on Thursday following an overnight drop on Wall Street that sent the Dow Jones industrial average below the 10,000 level for the first time since Feb 8.
Biosensors swings back to black with full-year net profit of US$32.1m
May 26th, 2010 |
No Comments
Biosensors International Group, the manufacturer of biodegradable drug-eluting stents, has reported a net profit of US$9.1 million ($12.9 million) in the fourth quarter ended 31 March 2010 (4Q FY2010) compared to a net profit of US$0.4 million in 4Q FY09.
Total product sales in 4Q FY10 were US$29.9 million ($42.2 million), a 46% increase over the same period a year ago, driven largely by continued growth in the sales of the BioMatrix drugâ€eluting stent across all regions.
Biosensors launches BioMatrix Flex drug-eluting stent
May 24th, 2010 |
No Comments
Biosensors International Group has launched its BioMatrix Flex drug-eluting stent system in major European markets and selected regions in the Middle East, Africa and Asia.
An extension of the company’s BioMatrix drug-eluting stent system, the company says BioMatrix Flex stent has received CE Mark approval for a comprehensive range of indications, including STEMI (ST elevated myocardial infarction), acute coronary syndromes and diabetes mellitus.
Biosensors gains 1.9% as China prospects stay solid, says Nomura
March 16th, 2010 |
No Comments
Biosensors (B20.SG) has gained 1.9% at 79.5 cents in active trade as investors relook at stock after 8.2% fall since beginning March, reported Dow Jones Newswires.
Recent weakness triggered partly by concerns over heart stent maker’s distribution business in Germany following Medtronics’ acquisition of Invatec, an affiliate Krauth Cardiovascular, which distributes Biosensors’ flagship BioMatrix stent in Germany, one of Europe’s major stent markets.
STI falls 0.3% to 2,736.93 at the break, ST Engineering, Biosensors, TPV up
February 1st, 2010 |
No Comments
The Straits Times Index slipped 0.3% to 2,736.93 as of the 12:30 p.m. About eight stocks dropped for every five shares that rose on the 30-member gauge, says Bloomberg newswires. Stocks on the measure trade at 14.6 times estimated earnings, compared with about 10 times at the start of 2009, according to data compiled by Bloomberg.
Biosensors gains after Nomura lifts share est on sales outlook
February 1st, 2010 |
No Comments
Biosensors International Group rose after Nomura Holdings Inc. raised its share-price forecast by 12% to $1.23, saying the sales outlook for the company’s drug-coated stents used to treat blocked arteries is strong.
{jcomments on}
Biosensors International Group rated buy
February 1st, 2010 |
No Comments
Nomura Research in a Jan 29 research report says: “Biosensors (BIG) reported a strong set of 3Q FY2010 results, with 9M net profit meeting 85% of our FY2010 forecast, underpinned by strong drug-eluting stent (DES) revenue growth (28% q-o-q) and contributions from JW Medical Systems (JWMS).
Biosensors posts 54% rise in 3Q sales to US$30m, net profit of US$12.4m
January 29th, 2010 |
No Comments
Biosensors International Group (BIG SP) today announced accelerated sales and earnings growth for its third fiscal quarter (3Q FY10) and nine months ended Dec 31 2009 (FY10 nineâ€month period).
Total product sales in the third quarter were US$29.8 million ($41.9 million), a 19% sequential increase over the previous quarter (2Q FY10), and a 54% increase over the same period a year ago (3Q FY09), driven largely by continued growth in the sales of the BioMatrix drugâ€eluting stent.
Biosensors receives CE Mark of approval for BioMatrix Flex
January 20th, 2010 |
No Comments
Biosensors International Group, the maker of drug-eluting stents, says it has received CE Mark of approval for a new version of its BioMatrix drug-eluting stent system, the BioMatrix Flex.
BioMatrix was originally launched in Europe in April 2008, where its unique combination of a Biosensors-developed abluminal biodegradable polymer and proprietary limus drug, Biolimus A9, rapidly proved successful.
Biosensors International Group rated buy
January 19th, 2010 |
No Comments
Nomura Research in a Jan 15 research report says: “In our view, the key focus in Biosensor’s (BIG) upcoming quarterly results should be sequential growth of its DES revenue; in the absence of new geographical launches, we believe q-o-q growth of above 10% should reaffirm the traction its flagship BioMatrix is garnering in existing markets.
Dec 7: Biosensors, CH Offshore, City Devs, Keppel
December 7th, 2009 |
No Comments
The following companies may have unusual price changes in trading, say Bloomberg and Thomson Reuters. Share prices are from the previous close. Singapore’s Straits Times Index dropped 0.6% to 2,791.01 last Friday.
US stocks advanced last Friday as data showed the economy shed far fewer jobs than expected last month, brightening the outlook for the economy and profits.
Bulk carriers: The Baltic Dry Index, which measures the cost of shipping commodities, gained 1.1% in London Dec. 4, taking gains in the past three days to 7.1%. Cosco Corp. Singapore (COS SP), a China-based shipbuilder that also operates bulk carriers, fell 1.8% to $1.07. Mercator Lines Singapore (MRLN SP), an Indian bulk carrier, was unchanged at 30.5 cents. STX Pan Ocean Co. (STX SP), South Korea’s biggest bulk carrier, slipped 1.8% to $13.44.
Biosensors, stent maker, jumps as Nomura says ‘buy’ on earnings
October 16th, 2009 |
No Comments
Biosensors International Group, a Singapore-based maker of drug-coated stents that treat blocked arteries, surged after Nomura Holdings Inc. recommended investors “buy” the stock.
The stock advanced 5.7% to 64.5 cents as 11:49 a.m. in Singapore, the sharpest since Aug. 13. Biosensors climbed 113% this year, compared with 54% rise for the benchmark Straits Times Index.
Biosensors International plans to issue bonds, warrants
October 13th, 2009 |
No Comments
Biosensors International Group said today it proposes to issue bonds and detachable warrants.
{jcomments on}
STI drops 0.4% to close at 2,650.48
September 9th, 2009 |
No Comments
The Straits Times Index dropped 0.4% to 2,650.48 at the close. The following shares were among the most active in the market.
Biosensors International Group (BIG SP), a maker of drug-coated stents that treat blocked arteries, climbed 4.2% to 62.5 cents, its highest level in a year. OCBC Investment Research Pte analyst Kelly Chia said Biosensors is a potential takeover target and maintained his “buy” rating in a report dated today.